[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 61 of about 61
1. Morais D, Ramírez B, Santos J: [Local sclerosing treatment with etoxiesclerol in ORL disease: Rendu-Osler disease, granuloma, angioma...]. Acta Otorrinolaringol Esp; 2002 Nov;53(9):658-61
Hazardous Substances Data Bank. DODECYL ALCOHOL, ETHOXYLATED .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Local sclerosing treatment with etoxiesclerol in ORL disease: Rendu-Osler disease, granuloma, angioma...].
  • [Transliterated title] El tratamiento local esclerosante con etoxiesclerol en la patología ORL: enfermedad de Rendu-Osler, granulomas, angiomas....
  • In a previous report, we showed the efficacy of the submucous sclerosant therapy with Etoxiesclerol (Polidocanol) in two patients with Rendu-Osler-Weber disease.
  • We confirm, in this present study, the advantages of Etoxiesclerol in the treatment of the epistaxis in the Rendu-Osler disease, in six patients, 3 males and 3 females and likewise in two patients with non-specific granuloma of nasal septum and another patient with cavernous hemangioma of soft palate.
  • [MeSH-major] Granuloma / drug therapy. Hemangioma, Cavernous / drug therapy. Palatal Neoplasms / drug therapy. Polyethylene Glycols / therapeutic use. Sclerosing Solutions / therapeutic use. Telangiectasia, Hereditary Hemorrhagic / drug therapy

  • Genetic Alliance. consumer health - Angioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12584880.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Sclerosing Solutions; 0AWH8BFG9A / polidocanol; 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


2. Mahasuar R, Kuruvilla A, Jacob K: Palatal tremor after lithium and carbamazepine use: a case report. J Med Case Rep; 2010;4:176

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Palatal tremor, characterized by rhythmic contractions of the soft palate, can occur secondary to pathology in the dentato-rubro-olivary pathway, or in the absence of such structural lesions.
  • We describe a case of probable drug-induced palatal tremor.
  • CASE PRESENTATION: A 27-year-old Indian man had taken carbamazepine and lithium for 7 years for the treatment of a manic episode.
  • He presented with a one-year history of bilateral rhythmic oscillations of his soft palate and tremors of his tongue.
  • CONCLUSION: Palatal tremors may result from medication used in the treatment of psychiatric disorders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Neurol. 2008;60(6):312-5 [18832845.001]
  • [Cites] Mov Disord. 2007 May 15;22(7):1038-43 [17357133.001]
  • [Cites] Mov Disord. 2007 Mar 15;22(4):573-6 [17260342.001]
  • [Cites] Dev Med Child Neurol. 2006 Dec;48(12):982-4 [17109787.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jun-Jul;27(6):1272-4 [16775278.001]
  • [Cites] Am Fam Physician. 2003 Oct 15;68(8):1545-52 [14596441.001]
  • [Cites] Brain. 2006 Apr;129(Pt 4):832-40 [16317025.001]
  • [Cites] Neurol Clin. 1995 May;13(2):283-97 [7643826.001]
  • [Cites] J Laryngol Otol. 1979 Feb;93(2):123-7 [429895.001]
  • [Cites] Brain. 2004 Jun;127(Pt 6):1252-68 [15090471.001]
  • [Cites] Epileptic Disord. 2006 Mar;8(1):77-80 [16567332.001]
  • (PMID = 20537197.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2901263
  •  go-up   go-down


3. Fabiani G, Teive HA, Sá D, Kay CK, Scola RH, Martins M, Werneck LC: Palatal myoclonus: report of two cases. Arq Neuropsiquiatr; 2000 Sep;58(3B):901-4
Hazardous Substances Data Bank. CLONAZEPAM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case 1: a 64 years old female who developed clicking sounds in both ears after a stroke and three years later on noticed a progressive involuntary movement of the throat associated with rhythmic contractions of the soft palate, muscles of tongue and throat.
  • Case 2: a 66 years old female who began with ear clicking at left ear that worsed slowly associated with tinnitus and arrhythmic movements of soft palate and an audible click at left ear.
  • [MeSH-major] Anticonvulsants / therapeutic use. Clonazepam / therapeutic use. Myoclonus / drug therapy. Serotonin Receptor Agonists / therapeutic use. Sumatriptan / therapeutic use
  • [MeSH-minor] Aged. Electromyography. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Palate, Soft / drug effects

  • Genetic Alliance. consumer health - Myoclonus.
  • Hazardous Substances Data Bank. Sumatriptan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11018829.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] BRAZIL
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Serotonin Receptor Agonists; 5PE9FDE8GB / Clonazepam; 8R78F6L9VO / Sumatriptan
  •  go-up   go-down


Advertisement
4. Castro LG, Müller AP, Mimura MA, Migliari DA: Hard palate perforation: an unusual finding in paracoccidioidomycosis. Int J Dermatol; 2001 Apr;40(4):281-3
Hazardous Substances Data Bank. KETOCONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hard palate perforation: an unusual finding in paracoccidioidomycosis.
  • A 36-year-old black man presented to his dermatologist in May 1996 complaining of mucosal lesions in the mouth, as well as perforation of the hard palate.
  • The hard and soft palate presented erythematous ulcers with a finely granulated base and irregular, but clearly defined margins.
  • A perforation (diameter, 0.5 cm) of the hard palate was seen in the center of the ulcerated region (Fig. 1).
  • Lung computed tomography (CT) exhibited findings consistent with pulmonary PCM.
  • Diagnosis of the chronic multifocal form of PCM with oral and pulmonary manifestations was established.
  • Drug therapy was initiated with ketoconazole (KCZ) 200 mg twice daily, which led to clinical cure in approximately 2 months.
  • Serum antibody values rose 30 days after institution of therapy (CIE 1 : 256; CF 1 : 512), peaking at day 60 (CIE 1 : 1024; CF 1 : 1024).
  • The hard palate perforation was corrected with a palatoplasty 27 months after initiation of drug therapy (Fig. 3).
  • KCZ was discontinued when serologic cure was achieved after 34 months of treatment (DI weakly positive; CIE 1 : 8; CF not measurable).
  • [MeSH-major] Palate, Hard / pathology. Paracoccidioidomycosis / microbiology
  • [MeSH-minor] Adult. Antifungal Agents / therapeutic use. Humans. Ketoconazole / therapeutic use. Male. Oral Surgical Procedures. Saccharomycetales / drug effects

  • Genetic Alliance. consumer health - Paracoccidioidomycosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11454087.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; R9400W927I / Ketoconazole
  •  go-up   go-down


5. Campistol-Plana J, Majumdar A, Fernández-Alvarez E: Palatal tremor in childhood: clinical and therapeutic considerations. Dev Med Child Neurol; 2006 Dec;48(12):982-4
Hazardous Substances Data Bank. PIRACETAM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palatal tremor in childhood: clinical and therapeutic considerations.
  • Palatal tremor (PT) is a rhythmic movement of the soft palate that often causes an ear click.
  • Several different treatments for EPT in children appear in the literature with variable reported efficacy.
  • It is concluded that piracetam is an effective drug for the treatment of EPT in children.
  • [MeSH-major] Essential Tremor / drug therapy. Neuroprotective Agents / therapeutic use. Palate, Soft. Piracetam / therapeutic use
  • [MeSH-minor] Child. Female. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Tremor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17109787.001).
  • [ISSN] 0012-1622
  • [Journal-full-title] Developmental medicine and child neurology
  • [ISO-abbreviation] Dev Med Child Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neuroprotective Agents; ZH516LNZ10 / Piracetam
  •  go-up   go-down


6. Major T, Sziklai I, Czeglédy J, Gáll T, Gergely L, Szarka K: Follow-up of HPV DNA copy number in cidofovir therapy of recurrent respiratory papillomatosis. Anticancer Res; 2008 Jul-Aug;28(4B):2169-74
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follow-up of HPV DNA copy number in cidofovir therapy of recurrent respiratory papillomatosis.
  • BACKGROUND: Cidofovir is a cytosine nucleoside analogue antiviral drug given as an adjuvant therapy in recurrent respiratory papillomatosis (RRP).
  • MATERIALS AND METHODS: Intralesional cidofovir therapy was given to a 14-year-old male patient.
  • Serial fresh-frozen biopsies were taken from the lesions in the larynx and soft palate prior to therapy and during its course.
  • After human papillomavirus (HPV) typing and the determination of the genomic physical state, the HPV DNA copy number was estimated with real-time PCR.
  • Prior to therapy, the HPV copy number fluctuated with time.
  • In the initial treatment period with 2-week-intervals both the viral load and the PSS decreased and a transient complete remission was observed.
  • CONCLUSION: The initial treatment period was successful, as the viral load decreased, and long-term effects of cidofovir might account for the controlled disease as the injection intervals were prolonged.
  • [MeSH-major] Cytosine / analogs & derivatives. DNA, Viral / genetics. Human papillomavirus 11 / genetics. Laryngeal Neoplasms / virology. Organophosphonates / therapeutic use. Papilloma / virology. Papillomavirus Infections / virology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Gene Dosage. Humans. Male. Mouth Neoplasms / drug therapy. Mouth Neoplasms / virology. Palate, Soft / pathology. Viral Load

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751391.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


7. Patel V, Mahajan S, Kharkar V, Khopkar U: Nasal extranodal NK/T-cell lymphoma presenting as a perforating palatal ulcer: a diagnostic challenge. Indian J Dermatol Venereol Leprol; 2006 May-Jun;72(3):218-21
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Examination revealed a perforation in the midline on the hard palate and a superficial ulcer on the soft palate.
  • Histopathology and immunohistochemistry suggested a diagnosis of extranodal nasal/nasal-type T-cell lymphoma.
  • The patient was started on multiagent chemotherapy in the form of cyclophosphamide, doxorubicin, vincristine and prednisolone but succumbed after two cycles.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Mouth Diseases / pathology. Nose Neoplasms / diagnosis. Oral Ulcer / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Killer Cells, Natural / pathology. Male. Mouth Neoplasms / diagnosis. Mouth Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16766838.001).
  • [ISSN] 0378-6323
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


8. Stadnikov AA, Chernova OL, Kovbyk LV, Shevliuk NN: [Effect of carnosine on the morphofunctional state of mucosal cells of the soft palate of rats in staphylococcal infection]. Zh Mikrobiol Epidemiol Immunobiol; 2000 Jul-Aug;(4 Suppl):59-62
MedlinePlus Health Information. consumer health - Staphylococcal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of carnosine on the morphofunctional state of mucosal cells of the soft palate of rats in staphylococcal infection].
  • The influence of carnosine on the morphofunctional state of mucosal cells of the soft palate of rats in experimental staphylococcal infection has been studied.
  • Morphological changes in muscular and connective tissue cells of the mucosa of the soft palate of rats have been found to occur.
  • The suppressive effect of carnosine with respect to the pathogen and its positive influence on the processes of the regeneration of eukaryotic tissues.
  • [MeSH-major] Carnosine / therapeutic use. Dipeptides / therapeutic use. Mouth Mucosa / drug effects. Palate, Soft / drug effects. Staphylococcal Infections / drug therapy. Staphylococcus aureus / metabolism
  • [MeSH-minor] Animals. Cells, Cultured. Connective Tissue / drug effects. Connective Tissue / microbiology. Connective Tissue / pathology. Morphogenesis / drug effects. Muscle, Skeletal / drug effects. Muscle, Skeletal / microbiology. Muscle, Skeletal / pathology. Rats. Regeneration / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12712515.001).
  • [ISSN] 0372-9311
  • [Journal-full-title] Zhurnal mikrobiologii, epidemiologii, i immunobiologii
  • [ISO-abbreviation] Zh. Mikrobiol. Epidemiol. Immunobiol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Dipeptides; 8HO6PVN24W / Carnosine
  •  go-up   go-down


9. Koussidis GA, Mountantonakis S, Petrichou CC: Folk remedies still in use: a case of soft palate and uvular oedema due to Ecbalium elaterium. Int J Clin Pract; 2002 Dec;56(10):817
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Folk remedies still in use: a case of soft palate and uvular oedema due to Ecbalium elaterium.
  • A case of soft palate and uvular oedema due to nasal administration of juice produced from the fruit of the plant Ecbalium elaterium, widely known as squirting cucumber, is presented.
  • [MeSH-major] Edema / etiology. Medicine, Traditional. Palate, Soft. Phytotherapy / adverse effects. Plant Preparations / adverse effects
  • [MeSH-minor] Female. Humans. Middle Aged. Sinusitis / drug therapy

  • MedlinePlus Health Information. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12510959.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Plant Preparations
  •  go-up   go-down


10. Chera BS, Amdur RJ, Hinerman RW, Morris CG, Villaret DB, Werning JW, Mendenhall WM: Definitive radiation therapy for squamous cell carcinoma of the soft palate. Head Neck; 2008 Aug;30(8):1114-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definitive radiation therapy for squamous cell carcinoma of the soft palate.
  • BACKGROUND: We report the University of Florida experience with soft-palate carcinoma treated with radiotherapy alone or combined with adjuvant chemotherapy and/or neck dissection for residual disease in the neck.
  • In multivariate analysis, overall treatment time significantly affected local and ultimate local-regional control, and nodal stage significantly affected overall survival.
  • CONCLUSIONS: The likelihood of cure after definitive radiotherapy is relatively high and is impacted by disease extent and overall treatment time.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Mouth Neoplasms / therapy. Palate, Soft / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neck Dissection. Neoplasm, Residual / surgery. Time Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18615732.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Erkal HS, Serin M, Amdur RJ, Villaret DB, Stringer SP, Mendenhall WM: Squamous cell carcinomas of the soft palate treated with radiation therapy alone or followed by planned neck dissection. Int J Radiat Oncol Biol Phys; 2001 Jun 1;50(2):359-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinomas of the soft palate treated with radiation therapy alone or followed by planned neck dissection.
  • PURPOSE: The present study presents the experience at the University of Florida with treatment of unselected patients with carcinomas of the soft palate with radiation therapy (RT) alone or followed by planned neck dissection.
  • T-stage and overall treatment time significantly affected local control in multivariate analysis.
  • Overall treatment time and planned neck dissection significantly affected nodal control in multivariate analysis.
  • Overall treatment time and planned neck dissection significantly affected ultimate local-regional control in multivariate analysis.
  • Overall stage, overall treatment time, and planned neck dissection significantly affected overall survival in multivariate analysis.
  • Overall treatment time and planned neck dissection significantly affected cause-specific survival in multivariate analysis.
  • CONCLUSION: For limited carcinomas of the soft palate, RT (alone or followed by planned neck dissection) results in relatively high local-regional control and survival rates.
  • For advanced carcinomas of the soft palate, local-regional control and survival rates are relatively low and local-regional recurrence rates are substantial.
  • Advanced carcinomas of the soft palate may be better treated with RT and concomitant chemotherapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neck Dissection. Neoplasm Staging. Palate, Soft / pathology. Palate, Soft / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11380222.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Poyrazoglu E, Dogru S, Saat B, Güngör A, Cekin E, Cincik H: Histologic effects of injection snoreplasty and radiofrequency in the rat soft palate. Otolaryngol Head Neck Surg; 2006 Oct;135(4):561-4
Hazardous Substances Data Bank. DODECYL ALCOHOL, ETHOXYLATED .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic effects of injection snoreplasty and radiofrequency in the rat soft palate.
  • OBJECTIVE: This study was undertaken to compare the effects of radiofrequency and injection snoreplasty on the histological structure of the soft palate in an animal model.
  • STUDY DESIGN AND SETTING: This is a blinded, controlled histologic evaluation of rat soft palates that underwent separate palatal interventions.
  • Then the soft palates were subjected to histological analysis.
  • CONCLUSION: Radiofrequency and injection snoreplasty stiffen the rat soft palate compared with controls.
  • [MeSH-major] Catheter Ablation. Palate, Soft / drug effects. Palate, Soft / surgery. Polyethylene Glycols / administration & dosage. Sclerosing Solutions / administration & dosage. Sclerotherapy. Snoring / pathology. Snoring / therapy

  • MedlinePlus Health Information. consumer health - Snoring.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011417.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sclerosing Solutions; 0AWH8BFG9A / polidocanol; 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


13. Cheriparambil KM, Vasireddy H, Kuruvilla A, Gambarin B, Makan M, Saul BI: Acute reversible cardiomyopathy and thromboembolism after cisplatin and 5-fluorouracil chemotherapy--a case report. Angiology; 2000 Oct;51(10):873-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute reversible cardiomyopathy and thromboembolism after cisplatin and 5-fluorouracil chemotherapy--a case report.
  • The authors report the successful management of such an event in a 52-year-old man with squamous cell carcinoma of the soft palate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cardiomyopathies / chemically induced. Cisplatin / adverse effects. Fluorouracil / adverse effects. Heart Diseases / chemically induced. Thromboembolism / chemically induced
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. Heart Ventricles / diagnostic imaging. Humans. Male. Middle Aged. Palatal Neoplasms / drug therapy. Ultrasonography


14. Srirompotong S, Tiamkao S, Jitpimolmard S: Botulinum toxin injection for objective tinnitus from palatal myoclonus: a case report. J Med Assoc Thai; 2002 Mar;85(3):392-5
MedlinePlus Health Information. consumer health - Tinnitus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five units of botulinum toxin A were injected into each side of the soft palate at the palatal muscles (levator veli palatini and tensor veli palatini muscle).
  • [MeSH-major] Botulinum Toxins, Type A / therapeutic use. Myoclonus / drug therapy. Neuromuscular Agents / therapeutic use. Tinnitus / etiology

  • Genetic Alliance. consumer health - Myoclonus.
  • Genetic Alliance. consumer health - Tinnitus.
  • MedlinePlus Health Information. consumer health - Botox.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12117033.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A
  •  go-up   go-down


15. Kawaguchi K: Robotic radiosurgery for severe recurrent and primary head and neck cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e17038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e17038 Background: We considered the functional reconstruction following head and neck tumor ablation, however, it was impossible to recover completely the function against the severe postoperative status.
  • Here we describe our aim to improve local control and to obtain organ preservation by using the non-surgical outpatient procedure the CyberKnife frameless radiosurgery (CK).
  • All the patients had biopsy confirmation of disease prior to radiation therapy; rT2 (3 patients), rT3 (8), rT4 (9), T2 (5), T3 (3), T4 (6), N1 (4), N2b (3), M1 (1), tongue (11), mandibule (11), maxilla (6), maxillary sinus (4), soft palate (2), with sq. cell ca.(34), adenoid cystic ca.(1), fibrosarcoma (1).
  • The treatment plan was set up based on CT, MRI and PET-CT in Yokohama CyberKnife Center.
  • For the primary cases, significant tumor reduction were noted at the third-month follow-up, all the 14 patients went into remission with 5 cases in CR, and 9 cases in PR.
  • Between the 4-6 month follow-up, 4 cases were performed additional CK treatment for the recurrent lesions, however, 3 patients with T4 tongue cancer were not cured.
  • Finally, the total control rate of the primary cases was 10/14 (71.4%), however, 8/9 (88.9%) primary cases except tongue cancer has been controlled treated by CK with chemotherapy.
  • There have been no seriously complications of treatment caused by CK except severe osteoradionecrosis of the 4 patients irradiated with maximum dose.
  • CONCLUSIONS: It is now possible with the development of CyberKnife Radiosurgery to improve our treatments of the local control in head and neck cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961782.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Majumdar S, Raghavan U, Jones NS: Solitary plasmacytoma and extramedullary plasmacytoma of the paranasal sinuses and soft palate. J Laryngol Otol; 2002 Nov;116(11):962-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plasmacytoma and extramedullary plasmacytoma of the paranasal sinuses and soft palate.
  • Radiotherapy is the common modality of treatment with, or without, adjuvant chemotherapy.
  • We report four cases of solitary plasmacytoma of the bone and an extramedullary plasmacytoma of the paranasal sinuses and soft palate.
  • [MeSH-major] Palatal Neoplasms / pathology. Palate, Soft / pathology. Paranasal Sinus Neoplasms / pathology. Plasmacytoma / pathology
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12487681.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Duggan VE, MacAllister CG, Davis MS: Xylazine-induced attenuation of dorsal displacement of the soft palate associated with epiglottic dysfunction in a horse. J Am Vet Med Assoc; 2002 Aug 1;221(3):399-401, 368

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xylazine-induced attenuation of dorsal displacement of the soft palate associated with epiglottic dysfunction in a horse.
  • An 18-month-old Quarter Horse filly was evaluated because of dorsal displacement of the soft palate associated with epiglottic dysfunction that caused exercise intolerance and an abnormal respiratory noise.
  • It was unusual that a complete response was obtained with xylazine hydrochloride, an alpha2-adrenergic agonist, although this drug has various effects on the respiratory tract in horses.
  • It was also unusual that the response outlasted the sedative effect of the drug.
  • [MeSH-major] Adrenergic alpha-Agonists / pharmacology. Epiglottis / drug effects. Horse Diseases / drug therapy. Respiratory Sounds / veterinary. Xylazine / pharmacology
  • [MeSH-minor] Animals. Female. Horses. Palate, Soft / abnormalities. Physical Conditioning, Animal. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12164538.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic alpha-Agonists; 2KFG9TP5V8 / Xylazine
  •  go-up   go-down


18. Penney SE, Bruce IA, Saeed SR: Botulinum toxin is effective and safe for palatal tremor: a report of five cases and a review of the literature. J Neurol; 2006 Jul;253(7):857-60
MedlinePlus Health Information. consumer health - Tinnitus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tinnitus is thought to be secondary to rhythmic involuntary movements of the soft palate.
  • After discussion with the patients with regard to the management of this condition and possible complications, five opted for botulinum toxin therapy and five declined further intervention.
  • Clinical diagnosis was made on the confirmation of soft palate movements synchronous with an audible clicking noise.
  • Of the five that were treated with toxin, four showed complete resolution of symptoms after a course of treatment.
  • This would suggest that botulinum toxin is a safe and effective first line treatment for palatal tremor.
  • [MeSH-major] Botulinum Toxins, Type A / administration & dosage. Myoclonus / drug therapy. Palate, Soft / drug effects. Tinnitus / drug therapy
  • [MeSH-minor] Female. Humans. Male. Muscle, Skeletal / drug effects. Muscle, Skeletal / physiopathology. Neuromuscular Agents / administration & dosage. Neuromuscular Agents / adverse effects. Neuromuscular Junction. Treatment Outcome

  • Genetic Alliance. consumer health - Tremor.
  • MedlinePlus Health Information. consumer health - Botox.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laryngol Otol. 1993 Mar;107(3):208-10 [8509697.001]
  • [Cites] Acta Otolaryngol Suppl. 2000;543:61-2 [10908979.001]
  • [Cites] J Otolaryngol. 1998 Aug;27(4):213-6 [9711516.001]
  • [Cites] Neurology. 1981 Jun;31(6):748-51 [7195491.001]
  • [Cites] Laryngoscope. 1984 Feb;94(2 Pt 1):217-9 [6694495.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1990;107(6):363-5 [2256608.001]
  • [Cites] Neurology. 1996 Apr;46(4):1168-9 [8780116.001]
  • [Cites] J Laryngol Otol. 1994 May;108(5):380-2 [8035114.001]
  • [Cites] J Laryngol Otol. 1987 Dec;101(12):1230-4 [3430042.001]
  • [Cites] Mov Disord. 2001 Jul;16(4):779-82 [11481715.001]
  • [Cites] J Med Assoc Thai. 2002 Mar;85(3):392-5 [12117033.001]
  • [Cites] Isr J Med Sci. 1994 Nov;30(11):816-9 [7982770.001]
  • [Cites] Otolaryngol Head Neck Surg. 1996 Feb;114(2):317-20 [8637761.001]
  • [Cites] Brain. 1990 Dec;113 ( Pt 6):1645-72 [2276039.001]
  • [Cites] Acta Otolaryngol. 2002 Jul;122(5):504-9 [12206259.001]
  • [Cites] Laryngoscope. 1982 Oct;92(10 Pt 1):1187-9 [7132522.001]
  • [Cites] Otol Neurotol. 2003 Sep;24(5):714-6 [14501444.001]
  • [Cites] Med Sci Monit. 2003 Feb;9(2):RA40-8 [12601305.001]
  • [Cites] Laryngoscope. 1961 Jun;71:668-71 [13738441.001]
  • [Cites] Int Tinnitus J. 2003;9(1):37-41 [14763328.001]
  • [Cites] Neurology. 1991 Oct;41(10):1677-9 [1922818.001]
  • (PMID = 16845571.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A
  •  go-up   go-down


19. Janas A, Grzesiak-Janas G: [Non-Hodgkin extranodular lymphoma of the palate]. Pol Merkur Lekarski; 2006 Jun;20(120):705-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin extranodular lymphoma of the palate].
  • In most cases, the extranodular localisation of the neoplasm is alimentary tract, particularly the stomach.
  • The aim of the study is to present a patient with rarely occuring lymphoma of the soft palate.
  • The patient was qualified for chemotherapy according to CHOP scheme, in the Chair of Oncology of Medical University in Lodz.
  • The patient completed the treatment in good condition.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Palate, Soft / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Humans. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007274.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


20. Silvestre FJ, Perez-Herbera A, Puente-Sandoval A, Bagán JV: Hard palate perforation in cocaine abusers: a systematic review. Clin Oral Investig; 2010 Dec;14(6):621-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hard palate perforation in cocaine abusers: a systematic review.
  • The vasoconstrictive and caustic effect of the drug can produce direct irritation and ischemia of the nasal and palatine mucosa, leading over the long term to the creation of an oronasal perforation secondary to maxillary bone destruction.
  • The main clinical characteristics of the disorder and its different management options are examined.
  • Likewise, emphasis is placed on the importance of a correct differential diagnosis with respect to other conditions also characterized by midfacial necrotic destruction.
  • Most of the lesions were located in the hard palate (77.7%) with only 5.5% being found in the soft palate.
  • Combined hard and soft palate presentations in turn accounted for 16.6% of the cases.
  • [MeSH-major] Cocaine-Related Disorders / complications. Nose Diseases / etiology. Oral Fistula / etiology. Palate, Hard / pathology. Respiratory Tract Fistula / etiology
  • [MeSH-minor] Bone Resorption / etiology. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Ischemia / etiology. Male. Maxillary Diseases / etiology. Mouth Mucosa / blood supply. Nasal Mucosa / blood supply

  • MedlinePlus Health Information. consumer health - Cocaine.
  • MedlinePlus Health Information. consumer health - Nose Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Oral. 2002 Mar-Apr;7(2):103-7 [11887017.001]
  • [Cites] Plast Reconstr Surg. 2003 Sep;112(3):914-5 [12960878.001]
  • [Cites] Ann Plast Surg. 1991 May;26(5):466-8 [1952721.001]
  • [Cites] Med Clin (Barc). 1991 Feb 9;96(5):189-93 [2033991.001]
  • [Cites] J Korean Med Sci. 2005 Aug;20(4):687-90 [16100468.001]
  • [Cites] Otolaryngol Head Neck Surg. 1997 Apr;116(4):565-6 [9141414.001]
  • [Cites] Neuropsychobiology. 2009;59(3):159-64 [19439996.001]
  • [Cites] Neth J Med. 2006 Jul-Aug;64(7):248-51 [16929087.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2008;61(5):588-90 [18321801.001]
  • [Cites] Ear Nose Throat J. 2002 Mar;81(3):172-7 [11913063.001]
  • [Cites] Ear Nose Throat J. 2001 Oct;80(10):738-40, 742-3 [11605572.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2009 Feb;62(2):e33-40 [18165165.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Sep;100(3):315-20 [16122659.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Apr;93(4):435-9 [12029282.001]
  • [Cites] J Craniomaxillofac Surg. 2007 Jun-Jul;35(4-5):241-5 [17870609.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Feb;35(2):150-4 [16181771.001]
  • [Cites] Acta Otorrinolaringol Esp. 2002 Feb;53(2):129-32 [11998527.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1998;255(9):446-7 [9833211.001]
  • [Cites] J Laryngol Otol. 2000 Aug;114(8):630-3 [11027056.001]
  • [Cites] Spec Care Dentist. 2000 Jul-Aug;20(4):139-42 [11203889.001]
  • [Cites] Med J Malaysia. 1998 Dec;53(4):435-8 [10971991.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2002 Feb;111(2):174-7 [11860072.001]
  • [Cites] J Rheumatol. 1990 Jun;17(6):838-40 [2388208.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1989 Feb;115(2):235-7 [2914096.001]
  • [Cites] Laryngoscope. 1989 Sep;99(9):918-24 [2770383.001]
  • [Cites] J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):286-7 [7829720.001]
  • [Cites] Ear Nose Throat J. 1996 Sep;75(9):623-6 [8870370.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2005 Oct;69(10):1395-8 [16023740.001]
  • [Cites] Am J Rhinol. 2003 Jan-Feb;17(1):33-43 [12693654.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 May 01;11(3):E239-42 [16648760.001]
  • [Cites] Med J Aust. 2002 Sep 2;177(5):260-2 [12197823.001]
  • [Cites] J Oral Maxillofac Surg. 1999 Aug;57(8):990-5 [10437727.001]
  • [Cites] Ear Nose Throat J. 2002 Aug;81(8):562-3 [12199175.001]
  • [Cites] Int J Dermatol. 2001 Apr;40(4):281-3 [11454087.001]
  • [Cites] Ear Nose Throat J. 2008 May;87(5):262 [18572780.001]
  • [Cites] J Can Dent Assoc. 1999 Apr;65(4):218-23 [10224723.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 May;99(5):594-7 [15829883.001]
  • [Cites] N Engl J Med. 2007 Nov 8;357(19):1956 [17989388.001]
  • [Cites] J Rheumatol. 2002 Aug;29(8):1795-7 [12180747.001]
  • [Cites] Int J Oral Maxillofac Surg. 2007 Aug;36(8):721-7 [17643265.001]
  • [Cites] Br Dent J. 2005 Mar 26;198(6):333-4 [15789087.001]
  • [Cites] Br Dent J. 2005 Sep 10;199(5):267-9 [16155536.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Oct;94(4):465-70 [12374921.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1988 Jan;114(1):90-1 [3334827.001]
  • [Cites] J Prosthet Dent. 1978 Apr;39(4):424-35 [273694.001]
  • (PMID = 20063023.001).
  • [ISSN] 1436-3771
  • [Journal-full-title] Clinical oral investigations
  • [ISO-abbreviation] Clin Oral Investig
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


21. Ogawa T, Hara K, Kawarai Y, Nishizaki K, Nomiya S, Takeda Y, Akagi H, Kariya S: A case of infantile neuroblastoma with intramucosal metastasis in a paranasal sinus. Int J Pediatr Otorhinolaryngol; 2000 Sep 15;55(1):61-4
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • His initial treatment included chemotherapy and surgery, with complete response (CR) being achieved at the initial site.
  • A metastatic lesion was found in the right maxillary sinus 32 months after his initial treatment.
  • A mass in the right soft palate was detected and was clinically suspected of being a metastasis.
  • The results of biopsy were negative and the differential diagnosis from the imaging studies of CT included odontogenic disease, fungal infection, paranasal sinus cyst or hematoma, and benign tumors.
  • The histopathological diagnosis was metastatic neuroblastoma from the adrenal lesion.
  • The local field was irradiated with 20 Gy of linear accelerator (linac) radiation, then the local field was eradicated.
  • Despite further treatment his general condition deteriorated rapidly and he died 24 months after starting treatment.
  • [MeSH-minor] Adrenalectomy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Child. Combined Modality Therapy. Disease Progression. Fatal Outcome. Humans. Male. Mucous Membrane / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10996238.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] IRELAND
  •  go-up   go-down


22. El Ghelbazouri N, Afifi Y, Benameur H, Bella A, Elhallaoui Y, Kettani F, Aït Ourhrouil M, Senouci K, Hassam B: [Oral verrucous carcinoma and human papillomavirus infection]. Ann Dermatol Venereol; 2007 Aug-Sep;134(8-9):659-62
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: A 72 year-old woman with a history of actinic cheilitis consulted for a bulky tumour of the lips and palate.
  • Clinical examination revealed a highly infiltrated labial tumour vegetating and budding, with a thick edge.
  • A bulky tumour and firm masses were seen on the hard and soft palates.
  • The immunohistochemical study showed intestinal tumour containing HPV-16 virus.
  • The central facial scan showed involvement of the nasal fossae, soft palate and lips with lysis of the upper maxilla arcade and the osseous palate.
  • The patient died a few days before the start of preoperative chemotherapy following severe deterioration of her general state.
  • Diagnosis is based on histological examination.
  • Management and treatment are not codified but surgery remains the treatment of choice and relapse is common in the case of locoregional involvement.
  • [MeSH-minor] Aged. Fatal Outcome. Female. Humans. Lip Neoplasms / pathology. Maxillary Diseases / pathology. Neoplasm Invasiveness. Nose Neoplasms / pathology. Osteolysis / pathology. Palatal Neoplasms / pathology. Palate, Hard / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925690.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Wu MD, Kimura M, Kusumi T, Taguchi A, Nakayama M, Inafuku S: ["Restricted ablation" of elongated uvula mucosa by the injection of the ethanol/steroid mixture: a new treatment for snoring and OSAS]. Nihon Jibiinkoka Gakkai Kaiho; 2005 Jan;108(1):15-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ["Restricted ablation" of elongated uvula mucosa by the injection of the ethanol/steroid mixture: a new treatment for snoring and OSAS].
  • We developed a "Submucosal Ethanol/Steroid (E/S) Injection Method (SEIM)" using an injection prepared by dissolving steroid with powerful antiinflammatory effect, which has the excellent effect of contractile reduction in oral tissues.
  • In this clinical trial, the ablation effect of SEIM on the abnormally elongated uvula and the soft palate was examined in each one clinical case of obstructive sleep apnea syndrome (OSAS) and simple snoring.
  • In the OSAS, we found that the uvula was reduced from 15 to 10mm, the visual analog scale (VAS) of snoring was reduced from 10 to 4 points, and the respiration disturbance index of the apnea-hypopnea index (AHI) improved from 35.3 to 26.1 after treatment.
  • In simple snoring, the uvula was reduced from 11 to 8.5mm and VAS was relieved from 7 to 2 points after treatment.
  • Our approach will produce a great clinical significance for not only OSAS or simple snoring but also treatment of the allergic rhinitis, etc, because the contractile tissue reduction can be attained safely in these diseases without open surgical wounds and unnecessary deformation or destruction of the mucosal structure.
  • [MeSH-major] Dexamethasone / administration & dosage. Dexamethasone / analogs & derivatives. Ethanol / administration & dosage. Sleep Apnea, Obstructive / drug therapy. Snoring / drug therapy
  • [MeSH-minor] Adult. Drug Combinations. Humans. Injections. Male. Middle Aged. Mouth Mucosa. Treatment Outcome. Uvula

  • MedlinePlus Health Information. consumer health - Snoring.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15712492.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] Case Reports; Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 312-93-6 / dexamethasone 21-phosphate; 3K9958V90M / Ethanol; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


24. Pradier O, Christiansen H, Ambrosch P, Kron M, Schmidberger H, Hess CF: A long-term follow-up study after split-course irradiation with concurrent chemotherapy (carboplatin) for locally advanced head and neck cancer and a review of the literature. ORL J Otorhinolaryngol Relat Spec; 2004;66(6):325-31
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-term follow-up study after split-course irradiation with concurrent chemotherapy (carboplatin) for locally advanced head and neck cancer and a review of the literature.
  • BACKGROUND: Radiotherapy is often the primary treatment for advanced head and neck cancer, but the rates of locoregional recurrence are high and survival is poor.
  • The purpose of this study was to evaluate the efficacy and toxicity of split-course radiotherapy combined with concurrent carboplatin chemotherapy after long-term follow-up.
  • Tumour localization in the oropharynx was: tonsil (n = 33), base of tongue (n = 28), soft palate (n = 2) and posterior pharyngeal wall (n = 3).
  • Forty-nine patients presented with a T(4) tumour, 15 were T(3) and 2 were T(2).
  • A total radiation dose of 5,670 cGy was applied in 6 weeks as a split-course regimen (2 x 2.1 Gy/day, 4 times a week, weeks 1 and 2 and weeks 5 and 6).
  • Concomitant carboplatin chemotherapy was given each radiotherapy day before irradiation (50 mg/m(2)).
  • Therapy was tolerated moderately (19% grade 3 skin reaction, 26% grade 3 mucositis, 23% grade 3 xerostomia, 20% grade 3 leucopenia, 8% grade 3 thrombopenia and 25% grade 3 anaemia).
  • CONCLUSION: Split-course radiotherapy and concomitant carboplatin chemotherapy can be carried out in inoperable head and neck cancer without severe toxicity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / methods. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel.
  • (PMID = 15668532.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  • [Number-of-references] 46
  •  go-up   go-down


25. Dahllöf G, Borgström P, Lundell G, Jacobsson H, Kogner P: Severe oral mucositis after therapeutic administration of [131I]MIBG in a child with neuroblastoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Oct;92(4):420-3
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe oral mucositis after therapeutic administration of [131I]MIBG in a child with neuroblastoma.
  • OBJECTIVE: The purpose of this report is to document a newly encountered oral side effect of targeted radiotherapy with iodine 131-metaiodobenzylguanidine ([(131)I]MIBG) in the treatment of neuroblastoma.
  • After completion of chemotherapy, the tumor showed no signs of regression; treatment with 3700 MBq [(131)I]MIBG was therefore decided on, 8 months after diagnosis.
  • RESULTS: Fourteen days after infusion of MIBG, severe oral mucositis was diagnosed, with a generalized erythema involving the mucous membranes of the hard and soft palate, buccal mucosa, and upper and lower lips.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11598577.001).
  • [ISSN] 1079-2104
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 35MRW7B4AD / 3-Iodobenzylguanidine
  •  go-up   go-down


26. Ito M, Tanaka J, Kubota K, Sato H, Takahashi M, Tanaka H, Ohdaira T, Yoshizawa H, Muramatsu Y, Satoh M, Suzuki E, Arakawa M, Gejyo F: [Obstructive sleep apnea syndrome in a patient with superior vena cava syndrome caused by lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2000 Jun;38(6):471-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 48-year-old man was treated with chemotherapy and irradiation therapy for superior vena cava syndrome (SVCS) caused by adenocarcinoma of the lung, and his symptoms subsided temporarily.
  • However, the same symptoms recurred, and severe snoring during sleep and daytime hypersomnolence developed.
  • After chemotherapy, the symptoms of edema of the face and arms, snoring, and daytime somnolence tendency were alleviated, and the patient's apnea hypopnea index decreased remarkably.
  • In addition, lateral cephalograms disclosed improved patency of the upper respiratory tract and dilation of the soft palate.
  • Therefore, it is necessary to determine whether OSAS is present and accordingly provide suitable treatment in patients with SVCS.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Sleep Apnea.
  • Genetic Alliance. consumer health - Superior vena cava syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10979287.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


27. Piperi E, Omlie J, Koutlas IG, Pambuccian S: Oral hairy leukoplakia in HIV-negative patients: report of 10 cases. Int J Surg Pathol; 2010 Jun;18(3):177-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight of the 10 patients were on steroid treatment for chronic obstructive pulmonary disease, 1 patient was on prednisone as part of a therapeutic regimen for gastrointestinal stromal tumor, and 1 patient did not have any history of immunosuppression.
  • Nine out of 10 lesions were located unilaterally on the tongue, whereas 1 lesion was located at the junction of the hard and soft palate.
  • Pathologists should be aware of OHL presenting not only in HIV-positive and HIV-negative organ transplant recipients but also in patients receiving steroid treatment, and more important, certain histologic features should raise suspicion for such diagnosis without prior knowledge of immunosuppression.
  • [MeSH-major] HIV Seronegativity. Leukemia, Hairy Cell / pathology. Leukoplakia, Hairy / pathology. Tongue Neoplasms / pathology. Tumor Virus Infections / pathology
  • [MeSH-minor] Adult. Aged. DNA, Viral / analysis. Female. Glucocorticoids / therapeutic use. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Humans. Immunocompromised Host. In Situ Hybridization. Male. Middle Aged. Mouth Mucosa / immunology. Mouth Mucosa / pathology. Mouth Mucosa / virology. Pulmonary Disease, Chronic Obstructive / complications. Pulmonary Disease, Chronic Obstructive / drug therapy. Pulmonary Disease, Chronic Obstructive / immunology

  • Genetic Alliance. consumer health - Leukoplakia.
  • Genetic Alliance. consumer health - Oral leukoplakia.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033322.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Glucocorticoids
  •  go-up   go-down


28. Pogorzelski R, Drozdowski W, Rogowski M: Symptomatic palatal myoclonus with ear click after tick-borne meningoencephalitis. Eur Arch Otorhinolaryngol; 2006 Aug;263(8):711-3
Genetic Alliance. consumer health - Myoclonus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three months after the treatment he started to complain of annoying, cracks-resembling, rhythmical sounds, coming from the inside of his head to both his ears.
  • Physical examination revealed rhythmical oscillations of the soft palate with a frequency of 100-120 per minute and a clock ticking noise synchronic with the palate tremor.
  • Treatment with several medications was started with no effect, then botulinum toxin was administered under EMG guidance to both sides of the patient's soft palate with great improvement.
  • A 5-year follow-up and continuation of botulinum toxin injections with only minor and reversible side effects proved the treatment efficacy and safety.
  • In the article we present a case of symptomatic palatal myoclonus with ear click and shortly discuss its aetiology, types and treatment options.
  • We also stress the efficacy and safety of PM treatment with repetitive injections of botulinum toxin.
  • [MeSH-major] Anti-Dyskinesia Agents / therapeutic use. Botulinum Toxins / therapeutic use. Encephalitis, Tick-Borne / complications. Myoclonus / drug therapy. Myoclonus / etiology
  • [MeSH-minor] Adult. Antibodies, Viral / blood. Antibodies, Viral / cerebrospinal fluid. Electromyography. Encephalitis Viruses, Tick-Borne / immunology. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Palate, Soft / physiopathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Otolaryngol. 1998 Aug;27(4):213-6 [9711516.001]
  • [Cites] Eur Neurol. 1997;38(2):133-4 [9286640.001]
  • [Cites] Acta Neurol Belg. 1996 Dec;96(4):270-80 [9008776.001]
  • [Cites] J Neurol. 2001 Nov;248(11):990-2 [11757966.001]
  • [Cites] Otolaryngol Pol. 2001;55(1):91-3 [11355486.001]
  • [Cites] Arch Neurol. 1986 Oct;43(10 ):1025-31 [3753263.001]
  • [Cites] Eur Neurol. 2002;48(1):52-3 [12138315.001]
  • [Cites] Brain. 1990 Dec;113 ( Pt 6):1645-72 [2276039.001]
  • [Cites] Eur Neurol. 1991;31(6):403-4 [1756767.001]
  • [Cites] Neurology. 1991 Apr;41(4):557-62 [2011257.001]
  • [Cites] Neurology. 1991 Oct;41(10):1677-9 [1922818.001]
  • [Cites] J Laryngol Otol. 1986 May;100(5):529-31 [3701200.001]
  • [Cites] Seizure. 2002 Mar;11(2):136-7 [11945102.001]
  • (PMID = 16703386.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Dyskinesia Agents; 0 / Antibodies, Viral; EC 3.4.24.69 / Botulinum Toxins
  •  go-up   go-down


29. Kühnel TS, Schulte-Mattler W, Bigalke H, Wohlfarth K: Treatment of habitual snoring with botulinum toxin: a pilot study. Sleep Breath; 2008 Mar;12(1):63-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of habitual snoring with botulinum toxin: a pilot study.
  • The objective of this study was to investigate whether injections of botulinum toxin into the soft palate reduce snoring in a subgroup of patients that present an active process causing habitual snoring.
  • Polysomnography was performed for diagnostic purposes and to monitor sleep quality before and after treatment.
  • The patients and their partners completed a questionnaire before and after treatment.
  • Recordings of snoring noise before and after treatment were evaluated on a visual analog scale by a blinded assessor.
  • Doses of 20 U of botulinum toxin type A (Dysport) were injected unilaterally into the muscles of the soft palate.
  • These results justify further studies of botulinum toxin therapy in patients with habitual snoring.
  • Therapy with botulinum toxin for habitual snoring is safe, non-invasive, easy to perform, fully reversible, and thus warrants investigation under placebo-controlled, double-blind conditions.
  • This treatment is appropriate for a disorder that is of paramount social importance but does not pose a medical threat to the individuals affected.
  • [MeSH-major] Botulinum Toxins, Type A / administration & dosage. Snoring / drug therapy
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Injections, Intramuscular. Male. Middle Aged. Palate, Soft / drug effects. Pilot Projects. Polysomnography / drug effects

  • MedlinePlus Health Information. consumer health - Botox.
  • MedlinePlus Health Information. consumer health - Snoring.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Otolaryngol Head Neck Surg. 1998 Sep;119(3):288-92 [9743085.001]
  • [Cites] N Engl J Med. 1993 Apr 29;328(17):1230-5 [8464434.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):335-40 [9089663.001]
  • [Cites] Can Med Assoc J. 1983 Mar 15;128(6):674-5 [6825032.001]
  • [Cites] Laryngoscope. 1996 Nov;106(11):1372-7 [8914903.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Apr;129(4):447-53 [12707193.001]
  • [Cites] Eur Respir J. 1996 Jan;9(1):146-59 [8834348.001]
  • [Cites] Dent Clin North Am. 2001 Oct;45(4):867-79 [11699245.001]
  • [Cites] Noise Health. 2002;4(15):57-60 [12678949.001]
  • [Cites] Lancet. 1994 Sep 3;344(8923):653-5 [7915351.001]
  • [Cites] J Neurol. 2006 Jul;253(7):857-60 [16845571.001]
  • (PMID = 17882462.001).
  • [ISSN] 1522-1709
  • [Journal-full-title] Sleep & breathing = Schlaf & Atmung
  • [ISO-abbreviation] Sleep Breath
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.4.24.69 / Botulinum Toxins, Type A
  •  go-up   go-down


30. Evans M, Powell NG: The changing aetiology of head and neck cancer: the role of human papillomavirus. Clin Oncol (R Coll Radiol); 2010 Sep;22(7):538-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human papillomavirus (HPV) is associated with the development of a subset of head and neck cancers arising in the oropharynx, which includes the tonsils, base of tongue and soft palate.
  • There is accumulating evidence from prospective studies that HPV-positive OPC responds better to treatment, including chemotherapy and radiotherapy, than HPV-negative OPC, and that patients with HPV-positive disease have excellent long-term survival rates.
  • To date, patients with HPV-positive and HPV-negative OPC are managed according to common treatment protocols; this may no longer be appropriate in an age when the delivery of targeted treatment, tailored to individual tumour and patient characteristics, is becoming a reality.
  • We also consider how knowledge of tumour HPV status may affect the future management and prevention of OPC and discuss the need for future collaborative trials in this important group of patients.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20584591.001).
  • [ISSN] 1433-2981
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


31. Muñoz JA, Marcoux M, Picandet V, Theoret CL, Perron MF, Lepage OM: Histological and biomechanical effects of palatal sclerotherapy in the horse using sodium tetradecyl sulfate. Vet J; 2010 Mar;183(3):316-21
MedlinePlus Health Information. consumer health - Choking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Palatal sclerotherapy using sodium tetradecyl sulfate has been suggested as a treatment for dorsal displacement of the soft palate in young Standardbred horses.
  • The present study evaluated histological and biomechanical changes in the equine soft palate following trans-endoscopic treatment with a low dose of this compound.
  • There was no variation in the density of palatal connective tissue between individuals, and on biomechanical assessment no significant difference in the stiffness of the palatal tissue was found between treated and control horses at any time.
  • The lower dose of sodium tetradecyl sulfate used in this study relative to previous reports, might explain the absence of tissue alterations.
  • This method of sclerotherapy did not alter the morphology or biomechanical properties of normal equine soft palates.
  • [MeSH-major] Airway Obstruction / veterinary. Horse Diseases / therapy. Sclerosing Solutions / therapeutic use. Sclerotherapy / veterinary. Sodium Tetradecyl Sulfate / therapeutic use
  • [MeSH-minor] Animals. Female. Horses. Male. Palate, Soft / drug effects. Palate, Soft / pathology. Physical Conditioning, Animal / physiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008. Published by Elsevier Ltd.
  • (PMID = 19109041.001).
  • [ISSN] 1532-2971
  • [Journal-full-title] Veterinary journal (London, England : 1997)
  • [ISO-abbreviation] Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Sclerosing Solutions; Q1SUG5KBD6 / Sodium Tetradecyl Sulfate
  •  go-up   go-down


32. Kulapaditharom B, Boonkitticharoen V: Photodynamic therapy in management of head and neck cancers and precancerous lesions. J Med Assoc Thai; 2000 Mar;83(3):249-58
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy in management of head and neck cancers and precancerous lesions.
  • Photodynamic therapy (PDT) is a new form of cancer treatment with low morbidity.
  • In this study, PDT was evaluated for its effectiveness in management of recurrent or widespread precancerous lesions, primary cancers in inoperable sites, recurrent or residual cancers which were refractory to radiotherapy and chemotherapy, and advanced tumors in the head and neck.
  • This was in contrast to cancers in the soft palate which failed in most cases possibly due to inadequate light dose distribution.
  • The mean follow-up time for this series was 28.3 months (range 3-66 months).
  • In conclusion, PDT is a useful modality for the treatment of head and neck tumors and precancerous lesions presenting in forms or under conditions that posed considerable difficulties in management by conventional approaches.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / pathology. Photochemotherapy / methods. Precancerous Conditions / drug therapy. Precancerous Conditions / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10808679.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] THAILAND
  •  go-up   go-down


33. van Veen RL, Nyst H, Rai Indrasari S, Adham Yudharto M, Robinson DJ, Tan IB, Meewis C, Peters R, Spaniol S, Stewart FA, Levendag PC, Sterenborg HJ: In vivo fluence rate measurements during Foscan-mediated photodynamic therapy of persistent and recurrent nasopharyngeal carcinomas using a dedicated light applicator. J Biomed Opt; 2006 Jul-Aug;11(4):041107

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo fluence rate measurements during Foscan-mediated photodynamic therapy of persistent and recurrent nasopharyngeal carcinomas using a dedicated light applicator.
  • The objective of this study was to evaluate the performance of a dedicated light applicator for light delivery and fluence rate monitoring during Foscan-mediated photodynamic therapy of nasopharyngeal carcinoma in a clinical phase I/II study.
  • We have developed a flexible silicone applicator that can be inserted through the mouth and fixed in the nasopharyngeal cavity.
  • Three isotropic fibers, for measuring of the fluence (rate) during therapy, were located within the nasopharyngeal tumor target area and one was manually positioned to monitor structures at risk in the shielded area.
  • A flexible black silicon patch tailored to the patient's anatomy is attached to the applicator to shield the soft palate and oral cavity from the 652-nm laser light.
  • We observed a systematic reduction in fluence rate during therapy in 20 out of 26 illuminations, which may be related to photodynamic therapy-induced increased blood content, decreased oxygenation, or reduced scattering.
  • [MeSH-major] Lighting / instrumentation. Mesoporphyrins / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy / instrumentation
  • [MeSH-minor] Adolescent. Adult. Equipment Design. Equipment Failure Analysis. Female. Humans. Indonesia. Light. Male. Photosensitizing Agents / therapeutic use. Pilot Projects. Radiation Dosage. Radiometry. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965135.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


34. Laccourreye O, Hans S, Ménard M, Garcia D, Brasnu D, Holsinger FC: Transoral lateral oropharyngectomy for squamous cell carcinoma of the tonsillar region: II. An analysis of the incidence, related variables, and consequences of local recurrence. Arch Otolaryngol Head Neck Surg; 2005 Jul;131(7):592-9
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTERVENTIONS: A total of 131 (81.9%) of the 166 patients received preoperative induction chemotherapy.
  • Fifty-one patients (30.7%) underwent postoperative radiation therapy.
  • In univariate analysis, 7 variables were significantly associated with an increased risk of local failure: increasing T classification; positive margins of resection; poor clinical response to induction chemotherapy; tumor spread to the posterior pillar, posterior pharyngeal wall, and contralateral soft palate; and invasion of the junction between the tonsil and soft palate.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local. Oropharynx / surgery. Tonsillar Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Logistic Models. Male. Middle Aged. Neoplasm Metastasis. Neoplasms, Second Primary. Otorhinolaryngologic Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16027281.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


35. Shin HA, Lim YC, Jeong HM, Choi EC: Role of primary surgery for early-stage (T1-2N0) squamous cell carcinoma of the oropharynx. Oral Oncol; 2009 Dec;45(12):1063-6
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate treatment outcomes and the role of primary definitive surgery for T(1-2), clinically N(0) oropharyngeal squamous cell carcinoma (OPSCC) patients, we performed a retrospective analysis of 46 consecutive cases treated primarily by surgery and/or postoperative radiotherapy at Yonsei University between May 1992 and December 2006.
  • The most common location was the tonsil (54%), followed by the soft palate (19%), the base of the tongue (BOT) (15%) and the posterior wall (12%).
  • Almost 30% of all patients may be candidates for adjuvant chemotherapy through histopathologic analysis according to the National Comprehensive Cancer Network (2007) guidelines.
  • The results of the present study demonstrate excellent oncologic outcomes with primary surgery for the treatment of early-stage OPSCC and suggest that surgery offers the best opportunity to identify patients in whom adjuvant radio- or chemotherapy may be most appropriately applied.
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Republic of Korea. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19717331.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. O'Connor-Reina C, Garcia-Iriarte MT, Gomez Angel D, Rodríguez-Diaz A: Bipolar radiofrequency uvulopalatoplasty combined with injection snoreplasty: a reasonable option for the problem of snoring. ORL J Otorhinolaryngol Relat Spec; 2009;71(2):105-11
MedlinePlus Health Information. consumer health - Snoring.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The aim of this study was to assess the effectiveness and morbidity of the combined use of bipolar radiofrequency uvulopalatoplasty and a sclerosing agent applied to the soft palate in patients with snoring and apnea during a 1-year follow-up period.
  • Under local anesthesia, a single procedure uvulopalatoplasty using bipolar radiofrequency applied with sterilized forceps was undertaken in combination with a sclerosing agent.
  • RESULTS: Four patients required a repeat procedure 6 weeks after the initial operation.
  • [MeSH-major] Catheter Ablation / instrumentation. Disorders of Excessive Somnolence / diagnosis. Endoscopy / methods. Palate, Soft / surgery. Sclerosing Solutions / therapeutic use. Snoring / drug therapy. Snoring / surgery. Uvula / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Equipment Design. Female. Humans. Male. Middle Aged. Postoperative Care. Prospective Studies. Severity of Illness Index. Sleep Apnea, Obstructive / diagnosis. Sleep Apnea, Obstructive / epidemiology. Surveys and Questionnaires. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19176981.001).
  • [ISSN] 1423-0275
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Sclerosing Solutions
  •  go-up   go-down


37. Nyst HJ, van Veen RL, Tan IB, Peters R, Spaniol S, Robinson DJ, Stewart FA, Levendag PC, Sterenborg HJ: Performance of a dedicated light delivery and dosimetry device for photodynamic therapy of nasopharyngeal carcinoma: phantom and volunteer experiments. Lasers Surg Med; 2007 Sep;39(8):647-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Performance of a dedicated light delivery and dosimetry device for photodynamic therapy of nasopharyngeal carcinoma: phantom and volunteer experiments.
  • The objective of this study was to develop a light delivery and measurement device for photodynamic therapy (PDT) in the nasopharyngeal cavity, which achieves a homogeneous and reproducible fluence rate distribution to a target area and provides proper shielding of predefined risk areas.
  • MATERIALS AND METHODS: A flexible silicone applicator was developed, incorporating light delivery and dosimetry fibers.
  • Tissue optical phantoms were prepared on the basis of optical properties measured in vivo using diffuse reflectance spectroscopy (DRS).
  • The fluence rate over the length of the applicator surface was measured in air, in tissue optical phantoms and in five healthy volunteers.
  • RESULTS: The fluence rate distribution over the applicator surface in air and tissue optical phantom was found to be more homogeneous (SD/mean 3.8% and 18.3%, respectively) than the fluence rate distribution in five volunteers (SD/mean ranging from 19% up to 52%).
  • Shielding of the risk area such as the soft palate and tongue was effective.
  • CONCLUSIONS: In air and in tissue optical phantoms the fluence rate distribution of the device was highly homogeneous.
  • Light delivery based on a single tissue surface measurement will not be adequate.
  • [MeSH-major] Light. Nasopharyngeal Neoplasms / drug therapy. Photochemotherapy / instrumentation. Photosensitizing Agents / administration & dosage. Radiometry / instrumentation
  • [MeSH-minor] Humans. Tissue Distribution

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17886277.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  •  go-up   go-down


38. Brennan B: Nasopharyngeal carcinoma. Orphanet J Rare Dis; 2006;1:23
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nasopharyngeal carcinoma (NPC) is a tumor arising from the epithelial cells that cover the surface and line the nasopharynx.
  • The tumor can extend within or out of the nasopharynx to the other lateral wall and/or posterosuperiorly to the base of the skull or the palate, nasal cavity or oropharynx.
  • Cervical lymphadenopathy is the initial presentation in many patients, and the diagnosis of NPC is often made by lymph node biopsy.
  • Symptoms related to the primary tumor include trismus, pain, otitis media, nasal regurgitation due to paresis of the soft palate, hearing loss and cranial nerve palsies.
  • The recommended treatment schedule consists of three courses of neoadjuvant chemotherapy, irradiation, and adjuvant interferon (IFN)-beta therapy.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Nasopharyngeal Neoplasms / diagnosis. Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / diagnosis. Child. Child, Preschool. Global Health. Humans. Incidence. Infant. Infant, Newborn. Neoplasm Staging / methods. Prognosis. Radiotherapy / methods. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Mar;41(3):1128-33 [638955.001]
  • [Cites] IARC Sci Publ. 1978;(20):115-29 [730188.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Apr;6(4):487-91 [7390929.001]
  • [Cites] Cancer. 1981 Jan 15;47(2):360-6 [7459824.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):163-9 [7053813.001]
  • [Cites] Med Pediatr Oncol. 1982;10(3):243-50 [7087893.001]
  • [Cites] Int J Cancer. 1983 Aug 15;32(2):171-6 [6874140.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1984 Sep-Oct;93(5 Pt 1):477-82 [6093669.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):956-61 [3940655.001]
  • [Cites] J Laryngol Otol. 1987 Dec;101(12):1248-53 [3323380.001]
  • [Cites] Int J Cancer. 1988 Aug 15;42(2):176-81 [2841245.001]
  • [Cites] Pediatr Hematol Oncol. 1986;3(2):143-52 [3153224.001]
  • [Cites] Cancer Res. 1994 Aug 1;54(15):4003-6 [8033130.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jun;3(4):305-10 [8061578.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1357-60 [8067705.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1188-91 [10096545.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):850-7 [15641027.001]
  • [Cites] Cancer. 2005 Sep 1;104(5):1083-9 [15999363.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5452-5 [10554016.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2351-5 [10811107.001]
  • [Cites] J Pediatr. 1974 Jan;84(1):96-100 [12119964.001]
  • [Cites] N Engl J Med. 2004 Jun 10;350(24):2461-70 [15190138.001]
  • [Cites] Arch Surg. 1967 Feb;94(2):214-7 [6016269.001]
  • [Cites] Nature. 1970 Dec 12;228(5276):1056-8 [4320657.001]
  • [Cites] Laryngoscope. 1972 May;82(5):807-16 [4337403.001]
  • [Cites] Nat New Biol. 1973 Aug 22;244(138):245-7 [4353684.001]
  • [Cites] J Pediatr. 1975 Feb;86(2):254-8 [1111694.001]
  • [Cites] Int J Cancer. 1975 Apr 15;15(4):651-7 [1173575.001]
  • (PMID = 16800883.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 36
  • [Other-IDs] NLM/ PMC1559589
  • [General-notes] NLM/ Original DateCompleted: 20070719
  •  go-up   go-down


39. Sakallioglu EE, Acikgoz G, Keles G, Senturk N, Karagoz F: Pemphigus vulgaris and complications of systemic corticosteroid therapy: a case report. J Oral Sci; 2003 Sep;45(3):165-9
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemphigus vulgaris and complications of systemic corticosteroid therapy: a case report.
  • Any part of the oral cavity may be affected, with the soft palate, buccal mucosa and lips being the most common sites.
  • In the present case, steroid treatment was begun at 180 mg/day and subsequently increased to 250 mg/day and 350 mg/day.
  • Respiratory problems occured, necessitating direct lung radiographs and computerised tomography.
  • Therefore, early diagnosis of oral symptoms is crucial for the successful treatment of PV.
  • [MeSH-major] Adrenal Cortex Hormones / adverse effects. Mouth Diseases / drug therapy. Pemphigus / drug therapy. Pulmonary Embolism / etiology


40. Ip MS, Tan KC, Peh WC, Lam KS: Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol (Oxf); 2001 Oct;55(4):477-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MEASUREMENTS: Subjects were assessed at baseline and those with apnoea-hypopnoea index (AHI) > or = 5 were reassessed after 6 months of treatment with Sandostatin LAR 20-30 mg IMI 4-weekly.
  • RESULTS: Of 14 subjects (age 42.0 +/- 8.1 years, mean +/- SD; 11 men) at baseline, there was a positive correlation between GH and tongue length (VT; P = 0.004), and between AHI and cephalometric indices: length of soft palate (PMU; P = 0.002); mandibular plane-hyoid bone distance (MPH; P = 0.017), maximum thickness of soft palate (Max-SP; P = 0.018) and VT (P = 0.027).
  • After treatment, there were significant improvements in hormonal profile: GH, mU/l (before, 51.5 +/- 27.8; after, 8.0 +/- 7.4; P = 0.017) and IGF-1, nmol/l (before, 95.5 +/- 23.4; after, 35.0 +/- 12.4; P = 0.012); sleep-disordered breathing: AHI (before, 29.4 +/- 22.6; after, 13.4 +/- 11.12; P = 0.025), snoring episodes (before, 486 +/- 240; after, 165 +/- 170; P = 0.05); cephalometric indices, mm: MPH (before, 18.8 +/- 12.1; after, 14.8 +/- 8.4; P = 0.018), VT (before, 72.3 +/- 4.4; after, 69.7 +/- 4.3; P = 0.05).
  • CONCLUSIONS: The findings demonstrated that there was correlation between sleep apnoea severity and soft tissue overgrowth at the upper airway region in acromegaly.
  • They also suggest that Sandostatin LAR improved obstructive sleep apnoea in acromegaly, and the effect might be partly mediated via a reduction in upper airway soft tissue, in particular that of the tongue, concomitant with a reduction in GH levels.
  • [MeSH-major] Acromegaly / complications. Antineoplastic Agents / therapeutic use. Octreotide / therapeutic use. Sleep Apnea Syndromes / complications. Sleep Apnea Syndromes / drug therapy. Somatostatin / analogs & derivatives
  • [MeSH-minor] Adult. Cephalometry. Female. Follow-Up Studies. Humans. Male. Polysomnography. Statistics, Nonparametric. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Sleep Apnea.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11678830.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 51110-01-1 / Somatostatin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


41. Halme PR, Antila J, Antila H, Aho H, Polo O, Salminiitty H, Toskala E: Uvulopalatopharyngoplasty with an ultrasound scalpel or laser: is there a difference? Eur Arch Otorhinolaryngol; 2010 Apr;267(4):635-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Uvulopalatopharyngoplasty (UPPP) is used for treatment of the obstructive sleep apnoea syndrome, mainly in the lower range of the apnoea-hypopnea index or partial upper airway obstruction.
  • Perioperative bleeding, operating room time and duration of operation together with histological injury of soft palate were analysed.
  • A postoperative follow-up questionnaire included a self analysis of pain, dietary intake and pain drug consumption.
  • In the same follow-up form, filled in by patients themselves, possible side effects and adequacy of pain medication together with any postoperative haemorrhage events were recorded during 10-day study period after UPPP.
  • The ultrasound scalpel group had significantly fewer haemorrhagic events (P = 0.037) during postoperative follow-up time after UPPP when compared to laser-assisted group.
  • [MeSH-major] Laser Therapy / instrumentation. Palate, Soft / diagnostic imaging. Palate, Soft / surgery. Pharynx / diagnostic imaging. Pharynx / surgery. Sleep Apnea, Obstructive / diagnostic imaging. Sleep Apnea, Obstructive / surgery. Uvula / diagnostic imaging. Uvula / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pain. 2003 Sep;4(7):407-14 [14622683.001]
  • [Cites] Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1738-45 [7952642.001]
  • [Cites] Surg Laparosc Endosc. 1995 Aug;5(4):255-62 [7551275.001]
  • [Cites] Laryngoscope. 1999 Dec;109(12):1950-4 [10591353.001]
  • [Cites] Ear Nose Throat J. 2004 Oct;83(10):707-10 [15586874.001]
  • [Cites] Anaesthesia. 2001 Nov;56(11):1045-50 [11703236.001]
  • [Cites] Fertil Steril. 1994 Mar;61(3):548-50 [8137982.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 Nov;129(5):577-81 [14595282.001]
  • [Cites] Laryngoscope. 2002 Aug;112(8 Pt 2 Suppl 100):14-6 [12172231.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Jan;134(1):106-13 [16399189.001]
  • [Cites] Eur Respir J. 1988 Apr;1(4):330-6 [3396673.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2004 Oct;29(5):530-4 [15373868.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1108-14 [10194153.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Mar;122(3):402-9 [10699818.001]
  • [Cites] Pain. 2003 Oct;105(3):415-23 [14527702.001]
  • [Cites] J Endourol. 1996 Oct;10(5):431-3 [8905489.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 May;263(5):449-54 [16311773.001]
  • [Cites] Surg Laparosc Endosc. 1994 Apr;4(2):92-9 [8180774.001]
  • [Cites] Obes Rev. 2001 Nov;2(4):267-74 [12119997.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Nov;125(5):449-55 [11700440.001]
  • [Cites] Ear Nose Throat J. 1993 Jan;72(1):67-72, 75-6 [8444132.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Jan;131(1):49-51 [15655185.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2002 Sep-Oct;64(5):339-42 [12417776.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2006 Aug;70(8):1389-96 [16551480.001]
  • [Cites] Lancet. 1994 Sep 3;344(8923):656-60 [7915352.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1989 Nov;115(11):1350-4 [2803716.001]
  • [Cites] Acta Anaesthesiol Scand. 1994 Oct;38(7):694-8 [7839779.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Apr;128(4):429-34 [11926920.001]
  • [Cites] J Dermatol Surg Oncol. 1988 Nov;14(11):1213-7 [3141490.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Oct;133(4):579-84 [16213933.001]
  • [Cites] Am J Surg. 1998 Jun;175(6):491-3 [9645779.001]
  • [Cites] Laryngoscope. 2000 Jul;110(7):1237-8 [10892704.001]
  • (PMID = 19609546.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Cox S, Zoellner H: Physiotherapeutic treatment improves oral opening in oral submucous fibrosis. J Oral Pathol Med; 2009 Feb;38(2):220-6
Genetic Alliance. consumer health - Oral submucous fibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physiotherapeutic treatment improves oral opening in oral submucous fibrosis.
  • The pathogenesis of OSF remains unclear, while surgical and pharmacological treatments have limited success, and are often inaccessible in communities using areca nut where OSF is prevalent.
  • Improved outcomes are reported for surgical treatment when followed by physiotherapy.
  • We tested the hypothesis that physiotherapy alone can modify tissue remodelling in OSF to increase oral opening.
  • MATERIALS AND METHODS: Fifty-four Nepali OSF patients were managed for 4 months in three randomly assigned groups receiving either: five times daily physiotherapy by inter-positioning tongue spatulas between teeth and adding a new spatula every 5-10 days; local injection of hyaluronidase with steroids; or no active treatment.
  • Progressive mucosal involvement was always in the same order, starting with the soft palate, and then progressing to the fauces, unilateral buccal mucosa, bilateral buccal mucosa, floor of mouth and finally lip mucosa (p < 0.006).
  • [MeSH-major] Mouth / physiopathology. Oral Submucous Fibrosis / physiopathology. Oral Submucous Fibrosis / therapy. Physical Therapy Modalities
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Hyaluronoglucosaminidase / therapeutic use. Male. Middle Aged. Nepal. Range of Motion, Articular. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18673417.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 3.2.1.35 / Hyaluronoglucosaminidase
  •  go-up   go-down


43. Kolokotronis A, Avramidou E, Zaraboukas T, Mandraveli K, Alexiou S, Antoniades D: Oral tuberculosis associated with a treatment with anti-rheumatic drugs. J Oral Pathol Med; 2006 Feb;35(2):123-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral tuberculosis associated with a treatment with anti-rheumatic drugs.
  • BACKGROUND: The use of immunosuppressive medication is a dominant risk factor for infection in patients with rheumatoid arthritis (RA).
  • Methotrexate (MTX) is one of the traditional disease-modifying antirheumatic drugs.
  • Adalimumab [a human anti-tumor necrosis factor-alpha (anti-TNF-alpha) monoclonal antibody] represent an important advance in the treatment of RA and has been recently come in use.
  • Infections occur at a high rate among those who use one or the combination of the two medications.
  • METHOD: We examined a female patient that was referred to our department for evaluation and treatment of a granular lesion on the soft palate and uvula, complaining of mild dysphagia.
  • CONCLUSIONS: The therapeutic use of MTX or/and adalimumab for the treatment of RA or few others diseases, can cause oral tuberculosis.
  • [MeSH-major] Antirheumatic Agents / therapeutic use. Arthritis, Rheumatoid / drug therapy. Immunosuppressive Agents / therapeutic use. Tuberculosis, Oral / diagnosis
  • [MeSH-minor] Adalimumab. Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Female. Humans. Methotrexate / therapeutic use. Mycobacterium tuberculosis / isolation & purification. Opportunistic Infections / diagnosis. Tuberculoma / diagnosis. Tumor Necrosis Factor-alpha / immunology

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430744.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antirheumatic Agents; 0 / Immunosuppressive Agents; 0 / Tumor Necrosis Factor-alpha; FYS6T7F842 / Adalimumab; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


44. Bassetti S, Wasmer S, Hasler P, Vogt T, Nogarth D, Frei R, Widmer AF: Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment. J Rheumatol; 2005 Nov;32(11):2125-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment.
  • OBJECTIVE: To compare the prevalence of nasal and oral Staphylococcus aureus in patients with rheumatoid arthritis (RA) with the prevalence in controls with other rheumatic diseases, and to determine predictors of S. aureus carriage and the influence of treatment with anti-tumor necrosis factor-a (anti-TNF-alpha) agents.
  • Quantitative nasal cultures for S. aureus were performed from swabs of the anterior nares, the posterior pharynx, and the soft palate.
  • Information on medications, medical conditions, and risk factors for S. aureus carriage was collected from all participants by a questionnaire and confirmed by chart review.
  • Treatment with anti-TNF-alpha agents was not associated with an increased S. aureus carriage rate.
  • However, treatment with an anti-TNF-alpha agent plus MTX may predispose patients to S. aureus carriage.
  • [MeSH-major] Arthritis, Rheumatoid / drug therapy. Arthritis, Rheumatoid / epidemiology. Staphylococcal Infections / epidemiology. Staphylococcus aureus / isolation & purification. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Adalimumab. Adult. Aged. Anti-Bacterial Agents / therapeutic use. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Antirheumatic Agents / administration & dosage. Antirheumatic Agents / adverse effects. Etanercept. Female. Humans. Immunoglobulin G / administration & dosage. Immunoglobulin G / adverse effects. Infliximab. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Microbiological Techniques. Middle Aged. Mouth / microbiology. Nose / microbiology. Oxacillin / therapeutic use. Prevalence. Receptors, Tumor Necrosis Factor / administration & dosage. Risk Factors

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. Etanercept .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16265689.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antirheumatic Agents; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab; FYS6T7F842 / Adalimumab; OP401G7OJC / Etanercept; UH95VD7V76 / Oxacillin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


45. Pogodzinski MS, Sabri AN, Lewis JE, Olsen KD: Retrospective study and review of polymorphous low-grade adenocarcinoma. Laryngoscope; 2006 Dec;116(12):2145-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequently affected sites were the hard palate (12 patients) and soft palate (9 patients).
  • Fifteen patients had their initial treatment at our institution, and four patients presented with a recurrent tumor.
  • One patient had regional nodal disease 20 years after the initial procedure, and another had lung metastasis.
  • No patients received chemotherapy.
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Salivary Glands, Minor


46. Lengyel E, Baricza K, Somogyi A, Olajos J, Pápai Z, Godény M, Németh G, Esik O: Reirradiation of locally recurrent nasopharyngeal carcinoma. Strahlenther Onkol; 2003 May;179(5):298-305
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To study the efficacy of reirradiation as salvage treatment in patients with locally recurrent nasopharyngeal carcinoma.
  • PATIENTS AND METHODS: Between 1993 and 2000, 20 consecutive patients (twelve males and eight females) with nasopharyngeal cancer, previously irradiated in different Hungarian institutions, were reirradiated for biopsy-proven locally recurrent tumor.
  • Histologically, 85% of the patients had WHO type III, 5% type II, and 10% type I disease.
  • The median time period between termination of primary treatment and local recurrence was 30 (range, 10-204) months.
  • Brachytherapy was the method most frequently used: in ten cases alone (especially for rT1 tumors), and in eight cases in combination with external beam therapy.
  • Two patients with locally advanced disease underwent external beam therapy only.
  • The median dose in the event of brachytherapy alone was 20 Gy (4 x 5 Gy or 5 x 4 Gy, range, 16-36 Gy), and the dose range for exclusive external irradiation was 30-40 Gy.
  • In cases of combined irradiation, a median 20-Gy brachytherapy (range, 16-40 Gy) was associated with 30-40 Gy of external irradiation.
  • Radiotherapy was supplemented by neck dissection (six patients), nasopharyngectomy (one patient), or chemotherapy (eleven patients).
  • RESULTS: 16 patients were reirradiated once, three twice, and one patient three times, with a median equivalent dose for tumor effect of 36 Gy (mean, 44 Gy; range, 19-117 Gy; the estimated alpha/beta-ratio was 10 Gy).
  • The median equivalent dose of reirradiation for late effect on normal tissue (with an estimated 70% delivery of the tumor dose) amounted to 30 Gy (mean, 37 Gy; range, 13-101 Gy, estimated alpha/beta-ratio 3 Gy).
  • Seven of the twelve surviving patients are currently tumor-free.
  • After primary irradiation, xerostomy occurred in all patients as an unavoidable side effect of treatment.
  • Following reirradiation, a severe (grade 3 or higher) late toxicity (CTC criteria, version 2) has been observed in two tumor-free patients (10%) so far (necrosis of soft palate and paresis of glossopharyngeal nerve).
  • [MeSH-major] Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Brachytherapy. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Radiotherapy / adverse effects. Radiotherapy Dosage. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12740656.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


47. Rusthoven KE, Raben D, Schneider C, Witt R, Sammons S, Raben A: Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node-positive tonsil cancer: results of a prospective management approach. Int J Radiat Oncol Biol Phys; 2009 Aug 1;74(5):1365-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To review the outcomes of a prospective management approach using ipsilateral neck radiotherapy in the treatment of node-positive squamous cell carcinoma of the tonsil with a well-lateralized primary lesion.
  • METHODS AND MATERIALS: Between August 2003 and June 2007, 20 patients who presented with squamous cell carcinoma of the tonsil, without involvement of the base of the tongue or midline soft palate, and with Stage N1-N2b disease were prospectively treated with radiotherapy to the primary site and ipsilateral neck.
  • In addition, 18 patients received concurrent chemotherapy.
  • Acute and late toxicity were prospectively evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3, and Radiation Therapy Oncology Group criteria.
  • Late Radiation Therapy Oncology Group grade 2 xerostomia occurred in 1 patient (5%).
  • CONCLUSION: In carefully selected patients with node-positive, lateralized tonsillar cancer, treatment of the ipsilateral neck and primary site does not appear to increase the risk of contralateral nodal failure and reduces late morbidity compared with historical controls.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Neck. Neoplasm Staging. Prospective Studies. Radiotherapy Dosage. Radiotherapy, Conformal / methods. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19168295.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Walsh TJ, Gonzalez CE, Piscitelli S, Bacher JD, Peter J, Torres R, Shetti D, Katsov V, Kligys K, Lyman CA: Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. J Clin Microbiol; 2000 Jun;38(6):2369-73
Hazardous Substances Data Bank. FLUCONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The procedures developed by the Antifungal Subcommittee of the National Committee for Clinical Laboratory Standards (NCCLS) are an important advance in standardization of in vitro antifungal susceptibility methodology.
  • In order to further understand the relationship between NCCLS methodology and antifungal therapeutic response, we studied the potential correlation between in vitro susceptibility to fluconazole and in vivo response in a rabbit model of fluconazole-resistant OPEC.
  • Rabbits infected with FS isolates and treated with fluconazole had significant reductions in oral mucosal quantitative cultures (P < 0.001) and tissue burden of C. albicans in tongue, soft palate, and esophagus (P < 0.001).
  • In comparison, rabbits infected with FR isolates were unresponsive to fluconazole and had no reduction in oral mucosal quantitative cultures or tissue burden of C. albicans versus untreated controls.
  • We conclude that there is a strong correlation between in vitro fluconazole susceptibility by NCCLS methods and in vivo response to fluconazole therapy of OPEC due to C. albicans.
  • [MeSH-major] Candidiasis / drug therapy. Candidiasis, Oral / drug therapy. Esophageal Diseases / drug therapy. Fluconazole / pharmacology. Microbial Sensitivity Tests / methods. Pharyngeal Diseases / drug therapy
  • [MeSH-minor] Animals. Child. Colony Count, Microbial. Disease Models, Animal. Drug Resistance, Microbial. Duodenum / microbiology. Female. Humans. Immunosuppression. Mouth / microbiology. Rabbits. Stomach / microbiology

  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • MedlinePlus Health Information. consumer health - Throat Disorders.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 1994 Oct;97(4):339-46 [7942935.001]
  • [Cites] J Infect Dis. 1994 Aug;170(2):384-9 [8035024.001]
  • [Cites] Antimicrob Agents Chemother. 1995 Jan;39(1):1-8 [7695288.001]
  • [Cites] J Antimicrob Chemother. 1995 Jan;35(1):103-14 [7768758.001]
  • [Cites] Antimicrob Agents Chemother. 1995 Mar;39(3):656-60 [7793868.001]
  • [Cites] J Infect Dis. 1996 Jan;173(1):219-25 [8537662.001]
  • [Cites] Antimicrob Agents Chemother. 1996 May;40(5):1277-9 [8723483.001]
  • [Cites] Antimicrob Agents Chemother. 1996 May;40(5):1317-20 [8723495.001]
  • [Cites] Antimicrob Agents Chemother. 1996 Jun;40(6):1342-5 [8725998.001]
  • [Cites] J Infect Dis. 1996 Oct;174(4):821-7 [8843222.001]
  • [Cites] J Antimicrob Chemother. 1996 Oct;38(4):671-7 [8937961.001]
  • [Cites] Antimicrob Agents Chemother. 1997 Jan;41(1):196-9 [8980781.001]
  • [Cites] Antimicrob Agents Chemother. 1997 Mar;41(3):575-7 [9055995.001]
  • [Cites] Clin Infect Dis. 1997 Feb;24(2):235-47 [9114154.001]
  • [Cites] J Chemother. 1997 May;9 Suppl 1:19-24 [9248959.001]
  • [Cites] J Med Vet Mycol. 1997 Jul-Aug;35(4):285-7 [9292427.001]
  • [Cites] J Clin Microbiol. 1987 May;25(5):931-2 [3294892.001]
  • [Cites] Lab Anim Sci. 1988 Aug;38(4):467-71 [3184859.001]
  • [Cites] Antimicrob Agents Chemother. 1989 Apr;33(4):467-9 [2543281.001]
  • [Cites] Rev Infect Dis. 1990 Mar-Apr;12 Suppl 3:S318-26 [2184510.001]
  • [Cites] Lab Invest. 1992 Apr;66(4):437-43 [1583884.001]
  • [Cites] J Pediatr. 1992 Jun;120(6):987-93 [1593362.001]
  • [Cites] Clin Infect Dis. 1994 Feb;18(2):240-2 [8161633.001]
  • [Cites] Antimicrob Agents Chemother. 1994 Jul;38(7):1530-3 [7979284.001]
  • (PMID = 10835005.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 8VZV102JFY / Fluconazole
  • [Other-IDs] NLM/ PMC86806
  •  go-up   go-down


49. Parlette EC, Polo JM: Case study: inoculation herpes barbae. Skinmed; 2005 May-Jun;4(3):186-7
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral exam showed shallow erosions on the tonsillar pillars and soft palate.
  • The patient was started on acyclovir 200 mg p.o. five times daily for 10 days.
  • [MeSH-minor] Acyclovir / therapeutic use. Adult. Antiviral Agents / therapeutic use. Face. Humans. Male. Stomatitis, Herpetic / drug therapy. Stomatitis, Herpetic / transmission

  • MedlinePlus Health Information. consumer health - Herpes Simplex.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15891258.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; X4HES1O11F / Acyclovir
  •  go-up   go-down


50. López-Pintor RM, Hernández G, de Arriba L, Morales JM, Jiménez C, de Andrés A: Oral ulcers during the course of cytomegalovirus infection in renal transplant recipients. Transplant Proc; 2009 Jul-Aug;41(6):2419-21
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to analyze the incidence, clinical characteristics, treatment, and outcome of renal transplant recipients with oral lesions due to CMV.
  • The affected oral locations included the buccal mucosa, hard palate, soft palate, tongue, and floor of the mouth.
  • CMV cases showed no significant difference with regard to gender distribution, age at renal transplantation, renal transplant indication, type of immunosuppressive treatment, and donor/recipient CMV serological status before transplantation.
  • The number of acute rejection episodes was significantly greater and time since transplantation was significantly shorter in CMV cases.
  • An early diagnosis of these lesions is important to a successful outcome for these patients.
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Immunosuppressive Agents / therapeutic use. Incidence. Kidney Diseases / surgery. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19715938.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


51. Werder P, Altermatt HJ, Zbären P, Mueller-Garamvölgyi E, Bornstein MM: Palatal swelling as the first and only manifestation of extranodal follicular non-Hodgkin lymphoma: a case presentation. Quintessence Int; 2010 Feb;41(2):93-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-Hodgkin lymphomas (NHLs) in the head and neck region are malignant lymphoid neoplasms that usually originate from B-lymphocytic cell lines.
  • Primary extranodal manifestations of this hematolymphoid tumor in the oral cavity are rare and involve the maxillary jaw including the palatal soft tissues, the mandible, and gingival tissues in patients between 60 and 70 years of age without sex predilection.
  • This case report of an extra-nodal NHL in the palate of a 75-year-old patient emphasizes the importance of accurate clinical, radiographic, and histologic diagnostic procedures to avoid delayed diagnosis or inappropriate treatment strategies.
  • Chemotherapy, radiotherapy, or a combination of the two with a regular clinical and hemic follow-up is recommended.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Palatal Neoplasms / pathology. Palate, Hard / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived / therapeutic use. Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Humans. Male. Palate, Soft / pathology. Remission Induction. Rituximab

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20165740.001).
  • [ISSN] 1936-7163
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


52. Mallia RJ, Subhash N, Sebastian P, Kumar R, Thomas SS, Mathews A, Madhavan J: In vivo temporal evolution of ALA-induced normalized fluorescence at different anatomical locations of oral cavity: application to improve cancer diagnostic contrast and potential. Photodiagnosis Photodyn Ther; 2010 Sep;7(3):162-75
MedlinePlus Health Information. consumer health - Mouth Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The focal goal of this study is to identify optimal accumulation periods for ALA-induced PpIX in different healthy anatomical sites of human oral cavity and different types of abnormal mucosa to improve the accuracy of the clinical applications such as photodiagnosis and tissue grading.
  • The optimal accumulation time in different anatomical sites of healthy subjects and abnormal tissues were determined by studying the temporal variation in normalized fluorescence intensities (NFI) at 635, 685 and 705 nm.
  • RESULTS AND DISCUSSIONS: In masticatory anatomical locations such as (gingival and hard palate) and in lining mucosa (inner lip, soft palate, floor of mouth, transition to floor of mouth, alveolus and ventral tongue) except vermillion border of lip (VBL) of healthy subjects (designated as group I), it was observed that optimum time for maximum accumulation of PpIX is 90 min.
  • In comparison, for lateral side of tongue (LST) and dorsal side of tongue (DST) tissues (designated as group II), maximum accumulation of PpIX was observed in 150 min of ALA application.
  • For diverse grade lesions of group I mucosa in patients, maximum accumulation of PpIX was observed in 90 min, whereas, in group II mucosa the optimum accumulation time was 150 min as in the case of healthy mucosa.
  • Further, between different grades oral mucosa, maximum variation in NFI take place at these optimal time periods.
  • CONCLUSIONS: The determination of the optimum accumulation time of ALA in oral mucosa based on NFI helps to improve the diagnostic contrast and accuracy of oral cancer diagnosis, and to plan appropriate timing for ensuing PDT.
  • [MeSH-major] Aminolevulinic Acid / pharmacokinetics. Mouth / metabolism. Mouth Diseases / diagnosis. Mouth Mucosa / anatomy & histology. Protoporphyrins / metabolism
  • [MeSH-minor] Administration, Topical. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Diagnosis, Oral. Humans. Mouth Neoplasms / diagnosis. Mouth Neoplasms / drug therapy. Mouth Neoplasms / pathology. Photochemotherapy. Spectrometry, Fluorescence. Time Factors

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20728840.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


53. Gironell A, Vives B, Pagonabarraga J: [Head tremor]. Rev Neurol; 2010 Jun 1;50(11):676-84
MedlinePlus Health Information. consumer health - Tremor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To review the symptomatology, aetiology and therapeutics of brain tremors.
  • DEVELOPMENT: Two main types of brain tremor can be distinguished: tremor of the whole brain (holocephalic tremor) and segmented brain tremor (tremor of the jaw, tongue, chin, soft palate, task-specific, orthostatic orolingual and undetermined).
  • Essential tremor, the main cause of brain tremor, and dystonic tremor give rise to holocephalic-type tremor in the vast majority of cases.
  • Brain tremor in Parkinsonism is characteristically of the segmented type.
  • The effectiveness of the pharmacological treatment of brain tremor is very limited.
  • Botulinum toxin is a promising therapy for brain tremors of any causation.
  • CONCLUSIONS: The semiological characteristics of brain tremor are a valuable aid in the aetiological diagnosis.
  • Pharmacological therapy is very limited.
  • [MeSH-minor] Botulinum Toxins / therapeutic use. Diagnosis, Differential. Humans. Parkinson Disease / physiopathology. Parkinson Disease / therapy

  • Genetic Alliance. consumer health - Tremor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514640.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] EC 3.4.24.69 / Botulinum Toxins
  • [Number-of-references] 44
  •  go-up   go-down


54. Shindo A, Taniguchi A, Nakano C, Sasaki R, Sugiyama T, Kuzuhara S: [Recurrent multiple cranial nerve palsy in a gravida with type 1 diabetes, that remitted after delivery and with steroid therapy]. Rinsho Shinkeigaku; 2008 Aug;48(8):579-82
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent multiple cranial nerve palsy in a gravida with type 1 diabetes, that remitted after delivery and with steroid therapy].
  • A 28-year-old woman with type 1 diabetes on insulin therapy developed left oculomotor nerve palsy in the fourth month of pregnancy.
  • Neurological examination revealed disturbance of sensation in the right side of the face, soft palate paresis, and bilateral atrophy and fasciculation of the tongue.
  • These symptoms remitted spontaneously after delivery, and the methylprednisolone pulse therapy accelerated the improvement.
  • [MeSH-major] Cranial Nerve Diseases / etiology. Diabetes Mellitus, Type 1 / complications. Prednisolone / administration & dosage. Pregnancy Complications / etiology. Pregnancy in Diabetics
  • [MeSH-minor] Adult. Delivery, Obstetric. Female. Humans. Pregnancy. Pulse Therapy, Drug. Recurrence


55. Rimal J, Sumanth KN, Ongole R, George T, Chatterjee S: A rare presentation of oral pemphigus vulgaris as multiple pustules. Kathmandu Univ Med J (KUMJ); 2007 Oct-Dec;5(4):541-5
Hazardous Substances Data Bank. DAPSONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report the first case of multiple pustules involving the lateral borders of tongue, buccal mucosa, hard palate, soft palate, vestibule and the gingiva of a 53 year old male.
  • The condition improved with systemic corticosteroid along with adjuvant therapy.
  • [MeSH-major] Mouth Mucosa / pathology. Pemphigus / diagnosis. Pemphigus / drug therapy
  • [MeSH-minor] Anti-Infective Agents / therapeutic use. Antirheumatic Agents / therapeutic use. Azathioprine / therapeutic use. Dapsone / therapeutic use. Diagnosis, Differential. Drug Therapy, Combination. Humans. Male. Middle Aged. Steroids / therapeutic use

  • Genetic Alliance. consumer health - Pemphigus.
  • Genetic Alliance. consumer health - Pemphigus vulgaris.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604092.001).
  • [ISSN] 1812-2078
  • [Journal-full-title] Kathmandu University medical journal (KUMJ)
  • [ISO-abbreviation] Kathmandu Univ Med J (KUMJ)
  • [Language] eng
  • [Publication-type] Classical Article; Journal Article
  • [Publication-country] Nepal
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Antirheumatic Agents; 0 / Steroids; 8W5C518302 / Dapsone; MRK240IY2L / Azathioprine
  •  go-up   go-down


56. Tisch M, Lampl L, Groh A, Maier H: Angioneurotic edemas of the upper aerodigestive tract after ACE-inhibitor treatment. Eur Arch Otorhinolaryngol; 2002 Sep;259(8):419-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioneurotic edemas of the upper aerodigestive tract after ACE-inhibitor treatment.
  • The pathomechanism of this side effect depends on an interaction of the drug with hormones regulating vascular permeability, such as the kallikrein kinin system and the prostaglandin system.
  • Angioedema is characterized by subcutaneous or submucosal swellings, which usually affect the lips, soft palate, tongue and larynx.
  • Pathomechanisms, differential diagnosis and treatment of ACE-inhibitor-induced edema of the upper aerodigestive tract are described in three case reports.
  • [MeSH-minor] Diagnosis, Differential. Digestive System Diseases / chemically induced. Digestive System Diseases / diagnosis. Digestive System Diseases / physiopathology. Digestive System Diseases / therapy. Epiglottis. Humans. Lip. Male. Middle Aged. Pharynx. Respiratory Tract Diseases / chemically induced. Respiratory Tract Diseases / diagnosis. Respiratory Tract Diseases / physiopathology. Respiratory Tract Diseases / therapy. Tongue

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12235515.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiotensin-Converting Enzyme Inhibitors
  •  go-up   go-down


57. Hirunwiwatkul P: Pain-relieving effect of local steroid injection in uvulopalatopharyngoplasty. J Med Assoc Thai; 2001 Jun;84 Suppl 1:S384-90
Hazardous Substances Data Bank. TRIAMCINOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Triamcinolone acetonide (Kenacort A) was injected onto the raw surface of the left-sided tonsillar fossa and left-sided soft palate after tonsillectomy and uvulopalatopharyngoplasty.
  • Other preoperative and post-operative medications including antibiotics, anesthesia and surgical techniques were standardized.
  • [MeSH-major] Anti-Inflammatory Agents / administration & dosage. Otorhinolaryngologic Surgical Procedures / methods. Pain, Postoperative / drug therapy. Palate, Hard / surgery. Pharynx / surgery. Triamcinolone / administration & dosage. Uvula / surgery
  • [MeSH-minor] Adult. Aged. Confidence Intervals. Female. Humans. Injections, Intralesional. Male. Middle Aged. Pain Measurement. Prospective Studies. Reference Values. Sleep Apnea, Obstructive / surgery. Tonsillectomy / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11529362.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 1ZK20VI6TY / Triamcinolone
  •  go-up   go-down


58. Tucci R, Aburad De Carvalhosa A, Anunciação G, Daumas Nunes F, Dos Santos Pinto D Jr: Late diagnosis of a primary oral malignant melanoma: a case report. Minerva Stomatol; 2010 Jan-Feb;59(1-2):55-9
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late diagnosis of a primary oral malignant melanoma: a case report.
  • Primary oral malignant melanoma (OMM) is a rare disease, representing 0.2% to 8% of all melanomas.
  • Eighty percent of the cases are located on the palate and maxillary gingiva, with the remainder found on the mandibular gingiva, buccal mucosa, tongue, and floor of the mouth.
  • OMM are highly aggressive with the tendency to metastasize and invade the surrounding tissues more readily than other oral malignancies.
  • The usual therapeutic approach for OMM is surgical excision of the primary tumor, supplemented by radiotherapy, with chemotherapy and immunotherapy serving as adjuvant.
  • Palpation revealed a painless soft tissue arising in maxillary gingiva, extending to the palate and vestibular mucosa.
  • The patient underestimated his symptoms and look for treatment after a substantial growth of the lesion.
  • This is an example of how a delayed detection affects the prognosis of OMM.
  • [MeSH-major] Gingival Neoplasms / diagnosis. Melanoma / diagnosis
  • [MeSH-minor] Adult. Delayed Diagnosis. Denial (Psychology). Fatal Outcome. Humans. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20212410.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


59. Guttal SS, Patil NP, Shetye AD: Prosthetic rehabilitation of a midfacial defect resulting from lethal midline granuloma--a clinical report. J Oral Rehabil; 2006 Nov;33(11):863-7
Genetic Alliance. consumer health - Midline lethal granuloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One of the causes of such defects is midline lethal granuloma, which is a destructive granulomatous lesion of uncertain aetiology, involving the nose, paranasal sinuses and the palate.
  • The patient had a severe midfacial defect involving the nose, the paranasal sinuses, the palate and the soft tissues of the face.
  • Although the lesion was not of the rapidly progressive type at the time of rehabilitation, the non-specific inflammatory process was persisting.
  • The patient was treated with chemotherapy and palliative therapy.
  • The primary objective of the prosthetic rehabilitation was to provide closure of the severe defect to protect the soft tissues from environmental exposure.
  • [MeSH-major] Granuloma, Lethal Midline / rehabilitation. Maxillofacial Prosthesis. Nose Deformities, Acquired / rehabilitation. Palate. Paranasal Sinus Diseases / rehabilitation
  • [MeSH-minor] Adult. Humans. Male. Mouth Diseases / rehabilitation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17002746.001).
  • [ISSN] 0305-182X
  • [Journal-full-title] Journal of oral rehabilitation
  • [ISO-abbreviation] J Oral Rehabil
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


60. Maurizio SJ, Eckart AL: A case study associated with oropharyngeal cancer. J Dent Hyg; 2010;84(4):170-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Squamous cell carcinoma (SCC) is the most common oral malignancy, commonly located on the anterior floor of the mouth, lateral borders of the tongue, tonsillar pillars and lateral soft palate.
  • A 59 year old male presented to a Midwestern university dental hygiene clinic following referral for pre-radiation and chemotherapy oral prophylaxis and comprehensive examination.
  • Biopsy confirmed the diagnosis of SCC of the left tonsil.
  • Surgery, radiation and chemotherapy were performed.
  • Dental hygienists should document significant findings and notify the dentist of abnormalities and the need for subsequent referral, providing early detection results in improved prognosis for those who encounter experiences with oral, head and neck cancer.

  • MedlinePlus Health Information. consumer health - Tooth Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21047462.001).
  • [ISSN] 1553-0205
  • [Journal-full-title] Journal of dental hygiene : JDH
  • [ISO-abbreviation] J Dent Hyg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Simon C, Goepfert H, Rosenthal DI, Roberts D, El-Naggar A, Old M, Diaz EM Jr, Myers JN: Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival. Eur Arch Otorhinolaryngol; 2006 Apr;263(4):313-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival.
  • Non-surgical therapy consisting of external beam radiation with or without chemotherapy is an effective treatment for patients with squamous cell carcinoma (SCC) of the oropharynx with advanced neck disease (N2a or greater).
  • It is reported that nearly 50% of the neck dissection specimens contain residual viable tumor cells that may indicate partial radiation failure and as a consequence poor survival.
  • In order to address the significance of this finding, we conducted a nonrandomized retrospective study, including 35 patients who underwent definitive radiation therapy followed by either a radical or modified radical (RND/MRND) or a selective neck dissection (SND) for clinically persistent neck disease 6 weeks after completing therapy for stage III/IV SCC of the oropharynx (base of the tongue =15, tonsil =12, soft palate =7 and pharyngeal wall =1).
  • All neck dissection specimens were reviewed according to histological criteria indicating viable residual tumor.
  • The presence of malignant tumor cells in residual disease in the neck correlated with poor disease-specific and overall survival (P =0.03 and P =0.01, respectively).
  • In conclusion, the presence of viable cancer cells in radiated neck nodes is a novel prognostic marker for disease-specific survival in patients treated for SCCs of the oropharynx with advanced neck disease and may serve as an identifier for patients who will benefit from post-treatment chemoprevention.
  • [MeSH-minor] Adult. Aged. Cell Survival. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Neoplasm, Residual. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(4):737-42 [1618666.001]
  • [Cites] Head Neck Surg. 1984 Jan-Feb;6(3):724-9 [6693288.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Mar;16(3):657-62 [2493434.001]
  • [Cites] Semin Radiat Oncol. 1992 Jul;2(3):163-170 [10717032.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jan 15;34(2):289-96 [8567328.001]
  • [Cites] Laryngoscope. 2000 Dec;110(12):2074-80 [11129024.001]
  • [Cites] Am J Surg. 1972 Oct;124(4):462-7 [5076159.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Head Neck. 2002 May;24(5):474-81 [12001078.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3964-71 [12351593.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Apr;124(4):401-6 [9559686.001]
  • [Cites] Head Neck. 2003 Nov;25(11):960-7 [14603457.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2967-80 [12115386.001]
  • [Cites] Head Neck. 1998 Mar;20(2):132-7 [9484944.001]
  • [Cites] CA Cancer J Clin. 2004 May-Jun;54(3):150-80 [15195789.001]
  • [Cites] Head Neck. 1999 Oct;21(7):606-13 [10487947.001]
  • (PMID = 16328403.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement